Pim-1 at the tumour microenvironment interface: context-specific mechanisms, evidence boundaries and therapeutic opportunities
Pim-1 has been implicated in oncogenic stress adaptation and selected tumour microenvironment interactions, raising interest in PIM-directed treatment. However, the evidence for a broad microenvironmental role remains uneven. Many reported effects derive from pan-PIM or non-exclusive inhibitors, other PIM family members or non-malignant models. Here, we evaluate Pim-1 biology at the tumour–microenvironment interface according to isoform attribution, intervention profile, cellular source, model system and endpoint directness. Pim-1-specific evidence is strongest for myeloid-derived suppressor cell metabolism, tumour-cell control of CCL2-dependent macrophage recruitment, hypoxia-inducible factor phosphorylation and CXCR4-dependent trafficking. Context-specific genetic evidence also supports roles in prostate stromal activation and murine myelofibrosis. By contrast, broad claims about immune remodelling, senescence-associated secretory control, solid-tumour fibrosis and several combination effects remain supported mainly by PIM-family pharmacology or indirect extrapolation. Clinical-stage PIM inhibitors remain pharmacologically heterogeneous, with limited single-agent activity, no validated predictive biomarker and no demonstration of isoform-specific target engagement linked to clinical benefit. We therefore propose a context-to-intervention framework in which disease state and cellular compartment identify the relevant PIM function. That function informs modality choice, while compartment-resolved target engagement links pharmacology to outcome. This framework provides a basis for distinguishing settings that justify selective Pim-1 targeting from those favouring family-wide inhibition or the use of PIM biology as a biomarker and combination rationale.
Authors
- Weimin Li (ORCID: https://orcid.org/0000-0003-0985-0311)
- Dandan Liang
- Silu Hu
- Ting Bao
- Jie Tang
- Ruiyao Luo
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Institute of Optics and Electronics, Chinese Academy of Sciences (CN)
Publication Details
- Journal
- Molecular Cancer
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1186/s12943-026-02833-0
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Science and Technology Major Project
- Fundamental Research Funds for the Central Universities
- West China Hospital, Sichuan University